摘要
结核病作为危害人类健康最重大的传染病,近年来在全球范围内又死灰复燃。随着多药耐药菌株的不断增加,原有的抗结核药物已不能满足临床的治疗要求,新型抗结核药物的研发迫在眉睫。本文选取了最新进入临床研究或临床前研究的抗结核候选药物,按照其不同的作用靶点综述了各个药物的药效学及药动学性质,为今后抗结核药物的研发提供参考和依据。
Tuberculosis, as the most significant infectious disease seriously threatening the human health, has worldwide reappeared in recent years. With the increase of multi-drug resistant strains, the current anti-TB drugs can no longer meet the requirements of clinical therapy. The research and development of new anti-TB drugs has been extremely urgent. This paper summarized the pharmacokinetics and pharmacodynamics of new anti-TB drug candidates for different targets, which are in clinical or preclinical studies. This will provide a reference to the future development of anti-TB drugs.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2013年第8期561-567,共7页
Chinese Journal of Antibiotics
关键词
结核分枝杆菌
药物靶点
新型抗结核药物
药动学
药效学
Mycobacterium tuberculosis
Drug target
New anti-tuberculosis
Pharmacokinetics
Pharmacodynamics
